Literature DB >> 29720399

Crystal structure of the human 4-1BB/4-1BBL complex.

Ryan N Gilbreth1, Vaheh Y Oganesyan2, Hamza Amdouni2, Shabazz Novarra2, Luba Grinberg2, Arnita Barnes2, Manuel Baca3.   

Abstract

4-1BBL is a member of the tumor necrosis factor (TNF) superfamily and is the ligand for the TNFR superfamily receptor, 4-1BB. 4-1BB plays an immunomodulatory role in T cells and NK cells, and agonists of this receptor have garnered strong attention as potential immunotherapy agents. Broadly speaking, the structural features of TNF superfamily members, their receptors, and ligand-receptor complexes are similar. However, a published crystal structure of human 4-1BBL suggests that it may be unique in this regard, exhibiting a three-bladed propeller-like trimer assembly that is distinctly different from that observed in other family members. This unusual structure also suggests that the human 4-1BB/4-1BBL complex may be structurally unique within the TNF/TNFR superfamily, but to date no structural data have been reported. Here we report the crystal structure of the human 4-1BB/4-1BBL complex at 2.4-Å resolution. In this structure, 4-1BBL does not adopt the unusual trimer assembly previously reported, but instead forms a canonical bell-shaped trimer typical of other TNF superfamily members. The structure of 4-1BB is also largely canonical as is the 4-1BB/4-1BBL complex. Mutational data support the 4-1BBL structure reported here as being biologically relevant, suggesting that the previously reported structure is not. Together, the data presented here offer insight into structure/function relationships in the 4-1BB/4-1BBL system and improve our structural understanding of the TNF/TNFR superfamily more broadly.
© 2018 Gilbreth et al.

Entities:  

Keywords:  T-cell biology; crystal structure; protein structure; protein-protein interaction; structural biology; structure-function; tumor necrosis factor (TNF)

Mesh:

Substances:

Year:  2018        PMID: 29720399      PMCID: PMC6016478          DOI: 10.1074/jbc.RA118.002803

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding.

Authors:  M J Eck; S R Sprang
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

2.  Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation.

Authors:  Hyun-Jung An; Young Jin Kim; Dong Hyun Song; Beom Suk Park; Ho Min Kim; Ju Dong Lee; Sang-Gi Paik; Jie-Oh Lee; Hayyoung Lee
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

Review 3.  Structural basis of signal transduction in the TNF receptor superfamily.

Authors:  Jixi Li; Qian Yin; Hao Wu
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

Review 4.  Modularity in the TNF-receptor family.

Authors:  J H Naismith; S R Sprang
Journal:  Trends Biochem Sci       Date:  1998-02       Impact factor: 13.807

5.  A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.

Authors:  Rebecca Leyland; Amanda Watkins; Kathy A Mulgrew; Nicholas Holoweckyj; Lisa Bamber; Natalie J Tigue; Emily Offer; John Andrews; Li Yan; Stefanie Mullins; Michael D Oberst; Jane Coates Ulrichsen; David A Leinster; Kelly McGlinchey; Lesley Young; Michelle Morrow; Scott A Hammond; Philip Mallinder; Athula Herath; Ching Ching Leow; Robert W Wilkinson; Ross Stewart
Journal:  Clin Cancer Res       Date:  2017-01-09       Impact factor: 12.531

Review 6.  Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.

Authors:  Cariad Chester; Miguel F Sanmamed; Jun Wang; Ignacio Melero
Journal:  Blood       Date:  2017-11-08       Impact factor: 22.113

Review 7.  Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.

Authors:  Miguel F Sanmamed; Fernando Pastor; Alfonso Rodriguez; Jose Luis Perez-Gracia; Maria E Rodriguez-Ruiz; Maria Jure-Kunkel; Ignacio Melero
Journal:  Semin Oncol       Date:  2015-06-11       Impact factor: 4.929

8.  Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: Implications for function.

Authors:  Kausik Chattopadhyay; Udupi A Ramagopal; Arunika Mukhopadhaya; Vladimir N Malashkevich; Teresa P Dilorenzo; Michael Brenowitz; Stanley G Nathenson; Steven C Almo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

Review 9.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Authors:  Todd Bartkowiak; Michael A Curran
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

10.  Human and mouse CD137 have predominantly different binding CRDs to their respective ligands.

Authors:  Ling Yi; Yanlin Zhao; Xiaojue Wang; Min Dai; Karl Erik Hellström; Ingegerd Hellström; Hongtao Zhang
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more
  8 in total

1.  Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Authors:  Christina Claus; Claudia Ferrara; Wei Xu; Johannes Sam; Sabine Lang; Franziska Uhlenbrock; Rosmarie Albrecht; Sylvia Herter; Ramona Schlenker; Tamara Hüsser; Sarah Diggelmann; John Challier; Ekkehard Mössner; Ralf J Hosse; Thomas Hofer; Peter Brünker; Catherine Joseph; Jörg Benz; Philippe Ringler; Henning Stahlberg; Matthias Lauer; Mario Perro; Stanford Chen; Christine Küttel; Preethi L Bhavani Mohan; Valeria Nicolini; Martina Carola Birk; Amandine Ongaro; Christophe Prince; Reto Gianotti; Gregory Dugan; Christopher T Whitlow; Kiran Kumar Solingapuram Sai; David L Caudell; Armando G Burgos-Rodriguez; J Mark Cline; Michael Hettich; Maurizio Ceppi; Anna Maria Giusti; Flavio Crameri; Wouter Driessen; Peter N Morcos; Anne Freimoser-Grundschober; Victor Levitsky; Maria Amann; Sandra Grau-Richards; Thomas von Hirschheydt; Stella Tournaviti; Michael Mølhøj; Tanja Fauti; Viola Heinzelmann-Schwarz; Volker Teichgräber; Sara Colombetti; Marina Bacac; Alfred Zippelius; Christian Klein; Pablo Umaña
Journal:  Sci Transl Med       Date:  2019-06-12       Impact factor: 17.956

2.  Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding.

Authors:  Aruna Bitra; Tzanko Doukov; Giuseppe Destito; Michael Croft; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2018-12-13       Impact factor: 5.157

3.  Inherited TNFSF9 deficiency causes broad Epstein-Barr virus infection with EBV+ smooth muscle tumors.

Authors:  Benjamin Fournier; Akihiro Hoshino; Anne-Sophie Defachelles; Bénédicte Neven; Julie Bruneau; Camille Bachelet; Mathieu Fusaro; Roman Klifa; Romain Lévy; Christelle Lenoir; Claire Soudais; Capucine Picard; Stéphane Blanche; Martin Castelle; Despina Moshous; Thierry Molina; Sylvain Latour
Journal:  J Exp Med       Date:  2022-06-03       Impact factor: 17.579

4.  4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling.

Authors:  Benjamin I Philipson; Roddy S O'Connor; Michael J May; Carl H June; Steven M Albelda; Michael C Milone
Journal:  Sci Signal       Date:  2020-03-31       Impact factor: 8.192

5.  GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells.

Authors:  Enli Liu; Sonny O T Ang; Lucila Kerbauy; Rafet Basar; Indreshpal Kaur; Mecit Kaplan; Li Li; Yijiu Tong; May Daher; Emily L Ensley; Nadima Uprety; Ana Karen Nunez Cortes; Ryan Z Yang; Ye Li; Hila Shaim; Francia Reyes Silva; Paul Lin; Vakul Mohanty; Sunil Acharya; Mayra Shanley; Luis Muniz-Feliciano; Pinaki P Banerjee; Ken Chen; Richard E Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 8.786

6.  Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering.

Authors:  Franziska Heckel; Anna H Turaj; Hayden Fisher; H T Claude Chan; Michael J E Marshall; Osman Dadas; Christine A Penfold; Tatyana Inzhelevskaya; C Ian Mockridge; Diego Alvarado; Ivo Tews; Tibor Keler; Stephen A Beers; Mark S Cragg; Sean H Lim
Journal:  Commun Biol       Date:  2022-03-14

7.  An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.

Authors:  Sarah Chan; Nicole Belmar; Sun Ho; Bryan Rogers; Marcia Stickler; Michelle Graham; Eileen Lee; Ninian Tran; Dong Zhang; Priyanka Gupta; Mien Sho; Tracy MacDonough; Andrew Woolley; Han Kim; Hong Zhang; Wei Liu; Pingping Zheng; Zoltan Dezso; Kyle Halliwill; Michele Ceccarelli; Susan Rhodes; Archana Thakur; Charles M Forsyth; Mengli Xiong; Siu Sze Tan; Ramesh Iyer; Marc Lake; Enrico Digiammarino; Li Zhou; Lance Bigelow; Kenton Longenecker; Russell A Judge; Cassie Liu; Max Trumble; Jonathan P Remis; Melvin Fox; Belinda Cairns; Yoshiko Akamatsu; Diane Hollenbaugh; Fiona Harding; Hamsell M Alvarez
Journal:  Nat Cancer       Date:  2022-03-07

8.  Targeting the 4-1BB costimulatory molecule through single chain antibodies promotes the human T-cell response.

Authors:  Salman Bagheri; Elmira Safaie Qamsari; Mehdi Yousefi; Farhad Riazi-Rad; Zahra Sharifzadeh
Journal:  Cell Mol Biol Lett       Date:  2020-04-22       Impact factor: 5.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.